NCT00196586View on ClinicalTrials.gov

Efficacy and Safety of Addition of IL-2 to Pegylated Interferon Alpha 2a and Ribavirin in HIV/HCV Coinfected Patients

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2003

Study Completion Date

November 30, 2006

Conditions

HIV InfectionsChronic Hepatitis C

Interventions

DRUG

Interleukin 2

DRUG

pegylated interferon alpha 2a

DRUG

ribavirin

Trial Locations (1)

75015

Hopital Européen Georges Pompidou, Paris

All Listed Sponsors

collaborator

Hoffmann-La Roche

INDUSTRY

lead

French National Agency for Research on AIDS and Viral Hepatitis

OTHER_GOV

NCT00196586 - Efficacy and Safety of Addition of IL-2 to Pegylated Interferon Alpha 2a and Ribavirin in HIV/HCV Coinfected Patients | Biotech Hunter | Biotech Hunter